FORT WORTH, Texas, Oct. 8, 2013 /PRNewswire/ -- Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the introduction of Regranex 360 ™ , a comprehensive new program to support patients in the U.S. using REGRANEX ™ Gel. REGRANEX Gel is the first and only FDA-approved platelet-derived growth factor (PDGF) therapy indicated as an adjunct to good ulcer care for the treatment of lower extremity diabetic neuropathic ulcers. 1
"We are very pleased to introduce the Regranex 360 program as part of our ongoing commitment to offer evidence-based biologic therapeutics along with best-in-class provider and patient support programs to the wound care market," said Rob Bancroft, President of Smith & Nephew Biotherapeutics. "In particular, we are delighted to streamline and enhance the REGRANEX Gel patient experience with a program designed to help each individual stay on track with their treatment."
Regranex 360 is a full service online portal designed to simplify the prior authorization and product acquisition process. In addition, to promote compliance and adherence to REGRANEX Gel, Regranex 360 provides each patient with a care coordinator they can contact via phone throughout their entire course of therapy.Regranex 360 is simple to use and access. Clinicians submit enrollment forms either through Regranex360.com or via fax. Regranex 360 then obtains prior authorization approval and forwards the prescription to an appropriate pharmacy. A patient care coordinator will contact the patient to schedule delivery, provide education and answer any questions about treatment. Patients can also contact the Regranex 360 hotline with any questions during their course of therapy. Regranex360.com is available to prescribers and patients 24 hours a day, 7 days a week; the hotline, 1-888-REGRANEX (734-7263) is accessible Monday through Friday, 8:00am to 7:00pm EST. In addition to the Regranex 360 program, Smith & Nephew Biotherapeutics has also launched a new REGRANEX Gel Web site ( www.Regranex.com) that highlights features of the product, including clinical research, provides a dosing calculator and offers additional tips for patients. Important Safety Information
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts